Drugs / BIO-106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05320588 | Mar 2022 → Apr 2024 overdue | cancer | BiOneCure Therapeutics Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BIO-106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05320588 ↗ |
| Modality | Other / unclassified | “BIO-106 is a novel antibody-drug conjugate (ADC)” NCT05320588 ↗ |